Drug repositioning, a new alternative in infectious diseases

Serafin, Marissa Bolson; Hörner, Rosmari

doi:10.1016/j.bjid.2018.05.007

Cited by 21 publications

(14 citation statements)

References 27 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Drug repurposing was immediately pursued to explore treatments for COVID-19 [ 56 , 57 ]. Repurposing is also known as repositioning, redirecting, and reprofiling [ 58 ]. It is a step to explore the application of an approved drug to treat different diseases from what it was originally developed for.…”

Section: Strategies Applied In Developing Protease Inhibitormentioning

confidence: 99%

Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease

Kang

2020

Microorganisms

104

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The viral outbreak started in late 2019 and rapidly became a serious health threat to the global population. COVID-19 was declared a pandemic by the World Health Organization in March 2020. Several therapeutic options have been adopted to prevent the spread of the virus. Although vaccines have been developed, antivirals are still needed to combat the infection of this virus. SARS-CoV-2 is an enveloped virus, and its genome encodes polyproteins that can be processed into structural and nonstructural proteins. Maturation of viral proteins requires cleavages by proteases. Therefore, the main protease (3 chymotrypsin-like protease (3CLpro) or Mpro) encoded by the viral genome is an attractive drug target because it plays an important role in cleaving viral polyproteins into functional proteins. Inhibiting this enzyme is an efficient strategy to block viral replication. Structural studies provide valuable insight into the function of this protease and structural basis for rational inhibitor design. In this review, we describe structural studies on the main protease of SARS-CoV-2. The strategies applied in developing inhibitors of the main protease of SARS-CoV-2 and currently available protein inhibitors are summarized. Due to the availability of high-resolution structures, structure-guided drug design will play an important role in developing antivirals. The availability of high-resolution structures, potent peptidic inhibitors, and diverse compound scaffolds indicate the feasibility of developing potent protease inhibitors as antivirals for COVID-19.

show abstract

Section: Strategies Applied In Developing Protease Inhibitormentioning

confidence: 99%

Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease

Kang

2020

Microorganisms

104

View full text Add to dashboard Cite

show abstract

“…The drug is being repositioned for other indications which could be of benefit to animals. For example, amitriptyline has been found to have significant antimicrobial activity against many bacterial species (Serafin & Hörner, 2018). Amitriptyline hydrochloride exhibits diverse pharmacological properties and thereby varied mechanisms of action.…”

mentioning

confidence: 99%

Modulation of nociception by amitriptyline hydrochloride in the Speke’s hinge‐back tortoise (Kiniskys spekii)

Makau

Towett

Abelson

et al. 2021

Veterinary Medicine & Sci

View full text Add to dashboard Cite

The biggest challenge in utilization of analgesics in reptiles has always been species specificity in respect to their effectiveness. Some analgesics considered to be generally effective in reptiles are not effective in certain reptile species. Mostly, pain in reptiles is commonly treated by use of non-steroidal anti-inflammatory drugs (NSAIDs), opioids and alpha-2 agonists (Sladky & Mans, 2012). There is also a plethora of potential analgesics for reptiles that are currently available and used in other vertebrate species. Tricyclic antidepressants for example are

show abstract

“…This method consists of finding new uses for clinically approved drugs that already have a known chemical structure, toxicity, and safety profile. Thus, they can be redirected in the treatment of emerging diseases and pandemics, due to their speed of implementation, effectiveness, and lower costs when compared to the development of a new drug (Ashburn and Thor 2004;Serafin and Hörner 2018;Peyclit et al 2019;Zhou et al 2020).…”

Section: Commentarymentioning

confidence: 99%

Anti-infective properties of proton pump inhibitors: perspectives

et al. 2021

Self Cite

View full text Add to dashboard Cite

Infectious diseases are among the main causes of morbidity and mortality today. In facing this crisis, the development of new drug options and combat strategies is necessary. In this sense, drug repositioning or drug redirection has emerged for the faster identification of effective drugs. In this "Commentary," the anti-infective properties of the class of proton pump inhibitors (PPIs) are emphasized. Studies report activities against bacterial, fungal, parasitic, and viral agents. In addition, we have provided in a table a summary of the specific characteristics of PPIs and some of their anti-infective activities.

show abstract

Drug repositioning, a new alternative in infectious diseases

Cited by 21 publications

References 27 publications

Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease

Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease

Modulation of nociception by amitriptyline hydrochloride in the Speke’s hinge‐back tortoise (Kiniskys spekii)

Anti-infective properties of proton pump inhibitors: perspectives

Contact Info

Product

Resources

About